SB-742457 And Donepezil In Alzheimer's Disease

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out if SB-742457 is a safe treatment and what effects it has on the symptoms of mild to moderate Alzheimer's Disease. SB-742457 is a new treatment which is thought to increase the levels of certain chemicals in the brain that are often decreased in patients with Alzheimer's Disease.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Donepezil

Criteria

Inclusion criteria:

• Clinical diagnosis of probable mild-to-moderate Alzheimer's Disease as determined by the NINCDS-ADRDA and DSM-IV criteria with an MMSE score of 12-24.

• Subjects and their caregivers must provide informed consent prior to study entry.

• Adequate blood pressure and laboratory values.

Exclusion criteria:

• Females of child-bearing potential.

• Have other causes of dementia such as vascular damage, depression, bipolar affective disorder, schizophrenia, syphilis, vitamin B12 deficiency or thyroid deficiency.

• Subjects taking medication for Alzheimers disease or centrally acting agents which might impact study outcomes.

• Subjects taking agents for which there is a theoretical risk of interaction with SB-742457 or donepezil.

• Subjects with conditions which might be exacerbated by exposure to donepezil.

• Subjects with known hypersensitivity to sunlight or seizures.